Free Trial

Cabaletta Bio (CABA) Stock Price, News & Analysis

Cabaletta Bio logo
$1.19 -0.05 (-3.95%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cabaletta Bio Stock (NASDAQ:CABA)

Key Stats

Today's Range
$1.14
$1.23
50-Day Range
$1.17
$2.71
52-Week Range
$1.15
$19.04
Volume
628,558 shs
Average Volume
1.49 million shs
Market Capitalization
$58.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
Consensus Rating
Buy

Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Remove Ads

Cabaletta Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

CABA MarketRank™: 

Cabaletta Bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 465th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cabaletta Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.34) to ($2.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cabaletta Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cabaletta Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cabaletta Bio has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cabaletta Bio's valuation and earnings.
  • Percentage of Shares Shorted

    14.14% of the float of Cabaletta Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently decreased by 7.84%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cabaletta Bio does not currently pay a dividend.

  • Dividend Growth

    Cabaletta Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.14% of the float of Cabaletta Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently decreased by 7.84%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cabaletta Bio has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 8 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 8 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Stock News Headlines

Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright
Guggenheim Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA)
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Cabaletta Bio price target lowered to $13 from $26 at Stifel
See More Headlines

CABA Stock Analysis - Frequently Asked Questions

Cabaletta Bio's stock was trading at $2.27 on January 1st, 2025. Since then, CABA shares have decreased by 46.9% and is now trading at $1.2050.
View the best growth stocks for 2025 here
.

Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01.

Cabaletta Bio (CABA) raised $87 million in an IPO on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

Last Earnings
8/08/2024
Today
4/03/2025
Next Earnings (Estimated)
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$50.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,674.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-67,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.51 per share
Price / Book
0.23

Miscellaneous

Free Float
44,048,000
Market Cap
$60.61 million
Optionable
Optionable
Beta
2.58
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CABA) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners